Newsletter Sign-Up

Keep up to date with NPC news and events by signing up for our e-newsletter E.V.I.dently, and our CER Daily Newsfeed.

Subscribe POLICY

NEWS FEEDS

Pharmaceutical Innovation’s Role in the Panorama of Health System Improvement and Population Health

November 17, 2015

When he announced the launch of the White House Precision Medicine Initiative, President Obama said, “If we have the opportunity to prevent hurt and heartbreak for more families; if we have the opportunity to help people live longer, happier, healthier lives….then we have to seize that.” The November 20 forum hosted by U.S. Department of Health and Human Services on pharmaceutical innovation, access and affordability provides an opportunity to discuss how we transform the President’s words into reality while establishing a health system that is financially sustainable and that offers the promise of better health to all Americans.

Many health stakeholders believe, and evidence would support the idea, that we are entering a golden age of innovation that will see a steady flow of new cures and treatments for devastating illnesses. In 2015 alone, the Food and Drug Administration has approved new medications for, among other conditions, chronic heart failure, Type 2 diabetes, breast cancer and cystic fibrosis. And new strides in genomic science and precision medicine are certain to catalyze more rapid therapeutic progress.

With these innovative breakthroughs, understandably, come concerns about cost and accessibility. As we embark on this conversation, and as we strive to strengthen an innovative environment that literally saves lives, it is essential that we not look at the cost of drug development in a vacuum, but rather the totality of these costs within the context of both time (the extent to which drug development can slow the escalation of, and the future costs associated with, chronic disease, as well as the inevitable decreasing of drug costs when competitors enter a therapeutic category’s marketplace) and space (the role of pharmaceutical innovation within a health care system in the process of transformation). 

It is unrealistic, for example, to talk about the cost of new cures and treatments without also discussing a health system that could be made much more cost efficient by eliminating hundreds of billions of dollars in waste. Studies have shown that, at a minimum, one of every five health care dollars is lost to overtreatment, breakdowns in care coordination and other system failures that stand to be repaired as the nation transitions to a pay-for-value approach to care delivery. As we determine how to curb overall health spending, it is a flawed direction to focus disproportionately on pharmaceutical development.

In fact, as we look at a present day in which chronic disease accounts for 86 percent of the nation’s health care costs and a future in which, for example, one of every three Americans is projected to be diabetic by the year 2050, we can’t have a productive conversation about short-term drug costs without also addressing the long-term financial and societal impact of chronic illness. In fact, as we address this issue, there are essential questions that need to be asked, such as:

  • How do we put all health care costs on the table to determine where we get the best long-term value in health care for patients, the economy and society?
  • Given the unique nature of the life cycle of pharmaceutical innovations, are there methods or tools that should be utilized, or developed, to weigh the potential long-term health savings generated by a new therapy versus its immediate costs?
  • Within health care payment systems, should policy makers encourage innovative risk mechanisms that would incentivize and optimize impactful drug development?

This is a discussion that will profoundly affect our nation’s health and future, and it’s a conversation NPC members are currently having. We look forward to continuing to share our ideas and perspectives on pharmaceutical innovation and accessibility for patients and consumers. Check back tomorrow for the next post in this series, and follow us on Twitter at @npcnow.

[Note: Read the other posts in this series, which focused on considering all health costsbalancing quality improvement with patient access as we shift to value-based care; and working together to ensure patient access to treatments and encourage innovation.]

Commentary and Testimony Page

The Importance of Evidence, Value, Access and Innovation in 2016

Last year, in our 2015 Health Care Outlook published in Chain Drug Review, I highlighted the recent announcement by the U.S. Department of Health and...
Newsletter Volume

E.V.I.dently November 2015

MessageCan We Work Together to Ensure Patient Access to Treatments and Encourage Innovation?Has biopharmaceutical innovation brought value and made a...
Blog Post

Can We Work Together to Ensure Patient Access to Treatments and Encourage Innovation?

Is it possible for all health care stakeholders to work together to develop solutions for containing costs that ensure patient access to care and...
Blog Post

At the HHS Pharmaceutical Forum, We Need to Consider All Health Care Costs

On November 20, stakeholders will come together for a day-long event—“HHS Pharmaceutical Forum: Innovation, Access, Affordability and Better Health”—...
Press Release

Specialty Medications: Shifting the Focus From “How Much” We Spend to “How Well” We Spend

Washington, DC, June 9, 2014—As health care decision-makers grapple with how to ensure access to specialty medications, the University of Michigan...
Press Release

National Pharmaceutical Council Welcomes Amgen as Its Newest Member

Washington, D.C. (January 16, 2013)—The National Pharmaceutical Council (NPC) today welcomed biotechnology pioneer Amgen as its newest member. Joshua...
Press Release

National Pharmaceutical Council Expands Policy and Research Staff

WASHINGTON, DC (January 4, 2012) -- The National Pharmaceutical Council (NPC) announced the hiring of Daryl Pritchard, PhD, as the Director of...
Press Release

New NPC Report Provides Guidance on Evaluating Comparative Effectiveness Studies

WASHINGTON, D.C. (December 10, 2009) – A new report released today by the National Pharmaceutical Council (NPC) provides guidance in the evaluation...
Commentary and Testimony Page

The Importance of Evidence, Value, Access and Innovation in 2016

Last year, in our 2015 Health Care Outlook published in Chain Drug Review, I highlighted the recent announcement by the U.S. Department of Health and...
Commentary and Testimony Page

Health Care Reform and Pharmaceutical Innovation

Although the Patient Protection and Affordable Care Act of 2010 (PPACA) is expected to have broad societal benefits, moving forward, it will be...
YouTube Videos

CER and Its Impact on Pharma Innovation

Dr. Darius Lakdawalla, director of research at the Schaeffer Center for Health Policy and Economics at the University of Southern California,...
Blog Post

Can We Work Together to Ensure Patient Access to Treatments and Encourage Innovation?

Is it possible for all health care stakeholders to work together to develop solutions for containing costs that ensure patient access to care and...
Blog Post

At the HHS Pharmaceutical Forum, We Need to Consider All Health Care Costs

On November 20, stakeholders will come together for a day-long event—“HHS Pharmaceutical Forum: Innovation, Access, Affordability and Better Health”—...
Blog Post

Value Is in the Eye of the Beholder? NPC Takes Closer Look at ICER Framework

In recent months, a number of health organizations have developed “value assessment frameworks,” which are designed to inform coverage and treatment...
Blog Post

#TBT: Innovation, Then and Now

As part of our “Throwback Thursday” blog series, we’re taking a look at a topic that’s currently in the news and tagging it with previous...

The Productivity Crisis in Pharmaceutical R&D

Although investment in pharmaceutical R&D has increased substantially in this time, the lack of...

Framing the Debate- Untangling the Potential Impact of Comparative Effectiveness Research on Innovation

Researchers integrated expert insight from a roundtable discussion into their own market research...
  •  
  • 1 of 4
  • >